CROWLEY, CRAIG,DESAUVAGE, FREDERIC J,EATON, DAN L,EBENS, ALLEN,POLSON, ANDREW,SMITH, VICTORIA
申请号：
NZ57835104
公开号：
NZ578351A
申请日:
2004.11.16
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed are CD22 Tumour Antigen of Haematopoietic Origin (THAO) proteins having at least 80% amino acid sequence identity to: (a) A polypeptide having the amino acid sequence shown in SEQ ID NO: 51 in figures 51A and B with or with its associated signal peptide (b) A polypeptide encoded by the nucleotide sequence shown in SEQ ID NO: 50 in Figures 50A and B or (c) A polypeptide encoded by the full-length coding region shown in SEQ ID NO: 50 in Figures 50A and B. Also disclosed are antibodies that bind the THAO that are conjugated via a peptidase-sensitive linker to a growth inhibitory or cytotoxic agent. The cytotoxic agent can be monomethylauristatin (MMAE), maytansinoid or calicheamicin, and the peptidase-sensitive linker can be a valine-citrulline (vc) linker. The antibodies are used for inhibiting unwanted cell growth.
